Microsatellite polymorphism within pfcrt provides evidence of continuing evolution of chloroquine-resistant alleles in Papua New Guinea

Table 2 Heterozygosity (± standard deviation) of MS loci associated with pfcrt-SVMNT^a allele in post-1995 samples.

Locus^c	Distance from *pfcrt*	Liksul n = 21	Dreikikir n = 16	Wosera^b n = 169
B5M77	-18 kb	0	.342 ± .140	.060 ± .026
2E10	-5 kb	0	.154 ± .126	.049 ± .024
msint1^d	0 kb	-	-	.051 ± .034^e
msint2	0 kb	.091 ± .081	.380 ± .134	.196 ± .039
msint3	0 kb	0	.314 ± .138	.056 ± .024
9B12	+2 kb	.181 ± .104	.275 ± .145	.045 ± .030
cg2	+7 kb	.450 ± .128	.275 ± .148	.220 ± .042
2H4	+19 kb	.710 ± .060	.781 ± .102	.746 ± .020
PfPK2	---	.617 ± .063	.769 ± .083	.744 ± .019

a 21/22 infections in Liksul, 16/31 in Dreikikir, and 169/761 in Wosera carried the pfcrt-SVMNT allele.
b Wosera group contains both clinical and community samples.
c PCR for Liksul samples was 100% for all loci except cg2 (.905). Frequency of amplification for each locus for Dreikikir and Wosera, respectively, were B5M77, 0.875, 0.970; 2E10, 0.813, 0.941; 9B12, 0.813, 0.941; cg2, 0.813, 0.976; 2H4, 0.875, 0.935; and PfPK2, 0.813, 0.935.
d MS also known as B5M47.
e Value based only on 78 of the 82 clinical samples and no community samples.

ISSN: 1475-2875